Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater anti-estrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen co...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Pharmacol Ther
Autori principali: Goetz, Matthew P., Sangkuhl, Katrin, Guchelaar, Henk-Jan, Schwab, Matthias, Province, Michael, Whirl-Carrillo, Michelle, Symmans, W. Fraser, McLeod, Howard L., Ratain, Mark J., Zembutsu, Hitoshi, Gaedigk, Andrea, van Schaik, Ron H., Ingle, James N, Caudle, Kelly E., Klein, Teri E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5931215/
https://ncbi.nlm.nih.gov/pubmed/29385237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1007
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi